| Expression pattern: |
DN |
| Associated gene: |
ATG4B, RNF5, ELAVL1 |
| Associated microRNA: |
- |
| Biological function: |
Promotes ATG4B liquid-liquid phase separation and RNF5-mediated ubiquitination, downregulates ATG4B, promotes anoikis, and suppresses gastric cancer metastasis/anoikis resistance. |
| Molecular mechanism: |
circSPECC1 binds ATG4B and promotes ATG4B LLPS, acting as a scaffold to enhance ATG4B interaction with E3 ligase RNF5, thereby promoting ubiquitin-dependent degradation of ATG4B; ELAVL1 binds m6A-modified circSPECC1 and inhibits its expression. |
| Biological pathway or process: |
autophagy (inhibits); metastasis (inhibits); apoptosis (promotes); other pathway/process (promotes); ubiquitination (promotes) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RIP (RNA Immunoprecipitation); RT-qPCR; RNA Pull-Down; Bioinformatics Analysis; Transfection; In Vivo Animal Model |
| Clinical significance: |
- |
| Description: |
In gastric cancer cells, circSPECC1 is down-regulated and functions as an ATG4B-binding circRNA that promotes ATG4B LLPS and RNF5-mediated ubiquitination, thereby reducing ATG4B protein levels to promote anoikis and suppress metastasis. ELAVL1 acts as an m6A reader that binds circSPECC1 and inhibits its expression, while lopinavir restores circSPECC1 abundance and suppresses GC metastasis. |
| Confidence score: |
0.6157 |